1月13日,美国疫苗厂商Moderna将其2025年销售预期下调了10亿美元以削减成本。该公司股价当天收盘暴跌17%。Moderna最新预计,2025年收入将在15亿美元至25亿美元之间,较去年9月的25亿美元至35亿美元的预期大幅下调。Moderna表示,这些销售额中的大部分将来自2025年下半年的新冠疫苗和新推出的呼吸道合胞病毒(RSV)疫苗销售。2024年,该公司这两款疫苗的收入约30亿美元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.